In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomet Expands Its Spine Play

Executive Summary

Biomet's recent acquisition of spine company InterporeCross expands its existing line of spine products but really is best seen as a follow-on to its recent buyout of its long-term alliance with German drug company Merck KGAA. Indeed, InterporeCross' major contribution in spine will come not in hardware, but in its strong orthobiologics program.

You may also be interested in...



Biomet's Rebirth?

Once the very model of stability among orthopedics companies, Biomet went through a rocky period a while ago as its stock price tanked and its long time CEO left the company. To the rescue has come a group of private equity investors who will take the company private when the transaction closes later this year. Biomet officials insist the company's turnaround will be based on the same success factors that made the company successful in the past: product innovation, strong distributor relationships, and close customer ties. But the question is: what changes, if any, will Biomet's new owners bring?

Dynamic Stabilization Rocks Spine

In the US acceptance of dynamic stabilization devices (DYNs) has been strong owing to the compelling advantages of DYNs over artificial discs, including that they can be implanted from a posterior route, do not violate the disc space and the procedure is reversible. Rather being an alternative to fusion, artificial discs will likely compete with DYNs.

Biomet Deal Opens Door for PE Buyers

A $10.9 billion bid by a consortium of private equity investors to buy Biomet raises questions about whether this is the first of many such deals or an outlier.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel